Karen Hodgson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Karen Hodgson has a total of 165 co-authors. Here are the top co-authors by number of shared publications:
- John Blangero
The University of Texas Rio Grande Valley
8 shared publications - Rudolf Uher
Dalhousie University
8 shared publications - Katherine E. Tansey
MRC Centre for Neuropsychiatric Genetics and Genomics, Institute of Psychological Medicine and Clinical Neurosciences, Cardiff School of Medicine, Cardiff University, Cardiff, UK
6 shared publications - Gerome Breen
King's College London
5 shared publications - Katherine J. Aitchison
Department of Psychiatry, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada
5 shared publications Nailin Yao
Department of Psychiatry Yale University School of Medicine New Haven Connecticut
5 shared publications
Latest Publications
- Open Access
Effects of the COVID-19 pandemic on the mental health of clinically extremely vulnerable children and children living with clinically extremely vulnerable people in Wales: A data linkage study
Objectives: To determine whether clinically extremely vulnerable (CEV) children or children living with a CEV person in Wales were at greater risk of presenting with anxiety or depression in primary or secondary care during the COVID-19 pandemic compared with children in the general population, and to compare patterns of anxiety and depression during the pandemic (23 rd March 2020–31 st January 2021, referred to as 2020/21) and before the pandemic (March 23rd 2019–January 31st 2020, referred to as 2019/20), between CEV children and the general population. Design: Population-based cross-sectional cohort study using anonymised, linked, routinely collected health and administrative data held in the Secure Anonymised Information Linkage Databank. CEV individuals were identified using the COVID-19 Shielded Patient List. Setting: Primary and secondary healthcare settings covering 80% of the population of Wales. Participants: Children aged 2–17 in Wales: CEV (3,769); living with a CEV person (20,033); or neither (415,009). Primary outcome measure: First record of anxiety or depression in primary or secondary healthcare in 2019/20 and 2020/21, identified using Read and ICD-10 codes. Results: A Cox regression model adjusted for demographics and history of anxiety or depression revealed that only CEV children were at greater risk of presenting with anxiety or depression during the pandemic compared with the general population (Hazard Ratio=2.27, 95% Confidence Interval=1.94–2.66, p<0.001). Compared with the general population, the risk amongst CEV children was higher in 2020/21 (Risk Ratio 3.04) compared with 2019/20 (Risk Ratio 1.90). In 2020/21, the cumulative incidence of anxiety or depression increased slightly amongst CEV children, but declined amongst the general population. Conclusions: Differences in the cumulative incidences of recorded anxiety or depression in healthcare between CEV children and the general population were largely driven by a reduction in presentations to healthcare services by children in the general population during the pandemic. Strengths and limitations of this study: Strengths of this study include its novelty, national focus and clinical relevance; to date this is the first population-based study examining the effects of the COVID-19 pandemic on healthcare use for anxiety or depression amongst clinically extremely vulnerable (CEV) children and children living with a CEV person in Wales We compared 2020/21 data with pre-pandemic 2019/20 data for CEV children and children in the general population, to place the impact of the COVID-19 pandemic in the context of longer-term patterns of healthcare use We used a novel approach and linked multiple datasets to identify a cohort of children living with a CEV person in Wales during the COVID-19 pandemic There was heterogeneity within the Shielded Patient List that was used to create the cohorts of children identified as CEV or living with a CEV person, in terms of the type and severity of individuals’ underlying conditions; the manner in which people were added to the list; the time point that people were added to the list; and the extent to which people followed the shielding guidance Routinely collected healthcare data does not capture self-reported health, and is likely to underestimate the burden of common mental disorders in the population
Open AccessEffects of the COVID-19 pandemic on the mental health of clinically extremely vulnerable children and children living with clinically extremely vulnerable people in Wales: A data linkage study
Objectives: To determine whether clinically extremely vulnerable (CEV) children or children living with a CEV person in Wales were at greater risk of presenting with anxiety or depression in primary or secondary care during the COVID-19 pandemic compared with children in the general population, and to compare patterns of anxiety and depression during the pandemic (23 rd March 2020–31 st January 2021, referred to as 2020/21) and before the pandemic (March 23rd 2019–January 31st 2020, referred to as 2019/20), between CEV children and the general population. Design: Population-based cross-sectional cohort study using anonymised, linked, routinely collected health and administrative data held in the Secure Anonymised Information Linkage Databank. CEV individuals were identified using the COVID-19 Shielded Patient List. Setting: Primary and secondary healthcare settings covering 80% of the population of Wales. Participants: Children aged 2–17 in Wales: CEV (3,769); living with a CEV person (20,033); or neither (415,009). Primary outcome measure: First record of anxiety or depression in primary or secondary healthcare in 2019/20 and 2020/21, identified using Read and ICD-10 codes. Results: A Cox regression model adjusted for demographics and history of anxiety or depression revealed that only CEV children were at greater risk of presenting with anxiety or depression during the pandemic compared with the general population (Hazard Ratio=2.27, 95% Confidence Interval=1.94–2.66, p<0.001). Compared with the general population, the risk amongst CEV children was higher in 2020/21 (Risk Ratio 3.04) compared with 2019/20 (Risk Ratio 1.90). In 2020/21, the cumulative incidence of anxiety or depression increased slightly amongst CEV children, but declined amongst the general population. Conclusions: Differences in the cumulative incidences of recorded anxiety or depression in healthcare between CEV children and the general population were largely driven by a reduction in presentations to healthcare services by children in the general population during the pandemic. Strengths and limitations of this study: Strengths of this study include its novelty, national focus and clinical relevance; to date this is the first population-based study examining the effects of the COVID-19 pandemic on healthcare use for anxiety or depression amongst clinically extremely vulnerable (CEV) children and children living with a CEV person in Wales We compared 2020/21 data with pre-pandemic 2019/20 data for CEV children and children in the general population, to place the impact of the COVID-19 pandemic in the context of longer-term patterns of healthcare use We used a novel approach and linked multiple datasets to identify a cohort of children living with a CEV person in Wales during the COVID-19 pandemic There was heterogeneity within the Shielded Patient List that was used to create the cohorts of children identified as CEV or living with a CEV person, in terms of the type and severity of individuals’ underlying conditions; the manner in which people were added to the list; the time point that people were added to the list; and the extent to which people followed the shielding guidance Routinely collected healthcare data does not capture self-reported health, and is likely to underestimate the burden of common mental disorders in the population
- Open Access
- 17 December 2019
- Published by JMIR Publications Inc. in JMIR Medical Informatics
- Vol. 7 (4) , e14782-152
Efficient Reuse of Natural Language Processing Models for Phenotype-Mention Identification in Free-text Electronic Medical Records: A Phenotype Embedding Approach
Background: Much effort has been put into the use of automated approaches, such as natural language processing (NLP), to mine or extract data from free-text medical records in order to construct comprehensive patient profiles for delivering better health care. Reusing NLP models in new settings, however, remains cumbersome, as it requires validation and retraining on new data iteratively to achieve convergent results. Objective: The aim of this work is to minimize the effort involved in reusing NLP models on free-text medical records. Methods: We formally define and analyze the model adaptation problem in phenotype-mention identification tasks. We identify “duplicate waste” and “imbalance waste,” which collectively impede efficient model reuse. We propose a phenotype embedding–based approach to minimize these sources of waste without the need for labelled data from new settings. Results: We conduct experiments on data from a large mental health registry to reuse NLP models in four phenotype-mention identification tasks. The proposed approach can choose the best model for a new task, identifying up to 76% waste (duplicate waste), that is, phenotype mentions without the need for validation and model retraining and with very good performance (93%-97% accuracy). It can also provide guidance for validating and retraining the selected model for novel language patterns in new tasks, saving around 80% waste (imbalance waste), that is, the effort required in “blind” model-adaptation approaches. Conclusions: Adapting pretrained NLP models for new tasks can be more efficient and effective if the language pattern landscapes of old settings and new settings can be made explicit and comparable. Our experiments show that the phenotype-mention embedding approach is an effective way to model language patterns for phenotype-mention identification tasks and that its use can guide efficient NLP model reuse.
- 17 December 2019
- Published by JMIR Publications Inc. in JMIR Medical Informatics
- Vol. 7 (4) , e14782-152
Open AccessEfficient Reuse of Natural Language Processing Models for Phenotype-Mention Identification in Free-text Electronic Medical Records: A Phenotype Embedding Approach
Background: Much effort has been put into the use of automated approaches, such as natural language processing (NLP), to mine or extract data from free-text medical records in order to construct comprehensive patient profiles for delivering better health care. Reusing NLP models in new settings, however, remains cumbersome, as it requires validation and retraining on new data iteratively to achieve convergent results. Objective: The aim of this work is to minimize the effort involved in reusing NLP models on free-text medical records. Methods: We formally define and analyze the model adaptation problem in phenotype-mention identification tasks. We identify “duplicate waste” and “imbalance waste,” which collectively impede efficient model reuse. We propose a phenotype embedding–based approach to minimize these sources of waste without the need for labelled data from new settings. Results: We conduct experiments on data from a large mental health registry to reuse NLP models in four phenotype-mention identification tasks. The proposed approach can choose the best model for a new task, identifying up to 76% waste (duplicate waste), that is, phenotype mentions without the need for validation and model retraining and with very good performance (93%-97% accuracy). It can also provide guidance for validating and retraining the selected model for novel language patterns in new tasks, saving around 80% waste (imbalance waste), that is, the effort required in “blind” model-adaptation approaches. Conclusions: Adapting pretrained NLP models for new tasks can be more efficient and effective if the language pattern landscapes of old settings and new settings can be made explicit and comparable. Our experiments show that the phenotype-mention embedding approach is an effective way to model language patterns for phenotype-mention identification tasks and that its use can guide efficient NLP model reuse.
Cannabis use, depression and self‐harm: phenotypic and genetic relationships
Background and Aims: The use of cannabis has previously been linked to both depression and self‐harm; however, the role of genetics in this relationship is unclear. This study aimed to estimate the phenotypic and genetic associations between cannabis use and depression and self‐harm.Design: Cross‐sectional data collected through UK Biobank were used to test the phenotypic association between cannabis use, depression and self‐harm. UK Biobank genetic data were then combined with consortia genome‐wide association study summary statistics to further test the genetic relationships between these traits using LD score regression, polygenic risk scoring and Mendelian randomization methods.Setting: United Kingdom, with additional international consortia data.Participants: A total of 126 291 British adults aged between 40 and 70 years, recruited into UK Biobank.Measurements: Phenotypic outcomes were life‐time history of cannabis use (including initial and continued cannabis use), depression (including single‐episode and recurrent depression) and self‐harm. Genome‐wide genetic data were used and assessment centre, batch and the first six principal components were included as key covariates when handling genetic data.Findings: In UK Biobank, cannabis use is associated with an increased likelihood of depression [odds ratio (OR) = 1.64, 95% confidence interval (CI) = 1.59–1.70] and self‐harm (OR = 2.85, 95% CI = 2.69–3.01). The strength of this phenotypic association is stronger when more severe trait definitions of cannabis use and depression are considered. Using consortia genome‐wide summary statistics, significant genetic correlations are seen between cannabis use and depression [rg = 0.289, standard error (SE) = 0.036]. Polygenic risk scores for cannabis use and depression explain a small but significant proportion of variance in cannabis use, depression and self‐harm within a UK Biobank target sample. However, two‐sample Mendelian randomization analyses were not significant.Conclusions: Cannabis use appeared to be both phenotypically and genetically associated with depression and self‐harm. Limitations in statistical power mean that conclusions could not be made on the direction of causality between these traits.
Cannabis use, depression and self‐harm: phenotypic and genetic relationships
Background and Aims: The use of cannabis has previously been linked to both depression and self‐harm; however, the role of genetics in this relationship is unclear. This study aimed to estimate the phenotypic and genetic associations between cannabis use and depression and self‐harm.Design: Cross‐sectional data collected through UK Biobank were used to test the phenotypic association between cannabis use, depression and self‐harm. UK Biobank genetic data were then combined with consortia genome‐wide association study summary statistics to further test the genetic relationships between these traits using LD score regression, polygenic risk scoring and Mendelian randomization methods.Setting: United Kingdom, with additional international consortia data.Participants: A total of 126 291 British adults aged between 40 and 70 years, recruited into UK Biobank.Measurements: Phenotypic outcomes were life‐time history of cannabis use (including initial and continued cannabis use), depression (including single‐episode and recurrent depression) and self‐harm. Genome‐wide genetic data were used and assessment centre, batch and the first six principal components were included as key covariates when handling genetic data.Findings: In UK Biobank, cannabis use is associated with an increased likelihood of depression [odds ratio (OR) = 1.64, 95% confidence interval (CI) = 1.59–1.70] and self‐harm (OR = 2.85, 95% CI = 2.69–3.01). The strength of this phenotypic association is stronger when more severe trait definitions of cannabis use and depression are considered. Using consortia genome‐wide summary statistics, significant genetic correlations are seen between cannabis use and depression [rg = 0.289, standard error (SE) = 0.036]. Polygenic risk scores for cannabis use and depression explain a small but significant proportion of variance in cannabis use, depression and self‐harm within a UK Biobank target sample. However, two‐sample Mendelian randomization analyses were not significant.Conclusions: Cannabis use appeared to be both phenotypically and genetically associated with depression and self‐harm. Limitations in statistical power mean that conclusions could not be made on the direction of causality between these traits.
- Open Access
- 22 May 2019
- Published by JMIR Publications Inc. in JMIR Preprints
Efficient Reuse of Natural Language Processing Models for Phenotype-Mention Identification in Free-text Electronic Medical Records: A Phenotype Embedding Approach (Preprint)
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Much effort has been put into the use of automated approaches, such as natural language processing (NLP), to mine or extract data from free-text medical records in order to construct comprehensive patient profiles for delivering better health care. Reusing NLP models in new settings, however, remains cumbersome, as it requires validation and retraining on new data iteratively to achieve convergent results. Objective: The aim of this work is to minimize the effort involved in reusing NLP models on free-text medical records. Methods: We formally define and analyze the model adaptation problem in phenotype-mention identification tasks. We identify “duplicate waste” and “imbalance waste,” which collectively impede efficient model reuse. We propose a phenotype embedding–based approach to minimize these sources of waste without the need for labelled data from new settings. Results: We conduct experiments on data from a large mental health registry to reuse NLP models in four phenotype-mention identification tasks. The proposed approach can choose the best model for a new task, identifying up to 76% waste (duplicate waste), that is, phenotype mentions without the need for validation and model retraining and with very good performance (93%-97% accuracy). It can also provide guidance for validating and retraining the selected model for novel language patterns in new tasks, saving around 80% waste (imbalance waste), that is, the effort required in “blind” model-adaptation approaches. Conclusions: Adapting pretrained NLP models for new tasks can be more efficient and effective if the language pattern landscapes of old settings and new settings can be made explicit and comparable. Our experiments show that the phenotype-mention embedding approach is an effective way to model language patterns for phenotype-mention identification tasks and that its use can guide efficient NLP model reuse.
- 22 May 2019
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessEfficient Reuse of Natural Language Processing Models for Phenotype-Mention Identification in Free-text Electronic Medical Records: A Phenotype Embedding Approach (Preprint)
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Much effort has been put into the use of automated approaches, such as natural language processing (NLP), to mine or extract data from free-text medical records in order to construct comprehensive patient profiles for delivering better health care. Reusing NLP models in new settings, however, remains cumbersome, as it requires validation and retraining on new data iteratively to achieve convergent results. Objective: The aim of this work is to minimize the effort involved in reusing NLP models on free-text medical records. Methods: We formally define and analyze the model adaptation problem in phenotype-mention identification tasks. We identify “duplicate waste” and “imbalance waste,” which collectively impede efficient model reuse. We propose a phenotype embedding–based approach to minimize these sources of waste without the need for labelled data from new settings. Results: We conduct experiments on data from a large mental health registry to reuse NLP models in four phenotype-mention identification tasks. The proposed approach can choose the best model for a new task, identifying up to 76% waste (duplicate waste), that is, phenotype mentions without the need for validation and model retraining and with very good performance (93%-97% accuracy). It can also provide guidance for validating and retraining the selected model for novel language patterns in new tasks, saving around 80% waste (imbalance waste), that is, the effort required in “blind” model-adaptation approaches. Conclusions: Adapting pretrained NLP models for new tasks can be more efficient and effective if the language pattern landscapes of old settings and new settings can be made explicit and comparable. Our experiments show that the phenotype-mention embedding approach is an effective way to model language patterns for phenotype-mention identification tasks and that its use can guide efficient NLP model reuse.
- Open Access
- 14 February 2019
- Published by Cold Spring Harbor Laboratory in bioRxiv
- p. 549899
Cannabis use, depression and self-harm: phenotypic and genetic relationships
Background and Aims: The use of cannabis has previously been linked to both depression and self-harm, however the role of genetics in this relationship are unclear. We aimed to examine the phenotypic and genetic relationships between these traits.Design: Genetic and cross-sectional phenotypic data collected through UK Biobank, together with consortia genome-wide association study summary statistics. These data were used to assess the phenotypic and genetic relationship between cannabis use, depression and self harm.Setting: UK, with additional international consortia dataParticipants: N=126,291 British adults aged between 40 and 70 years, recruited into UK BiobankMeasurements: Genome-wide genetic data, phenotypic data on lifetime history of cannabis use, depression and self-harm.Findings: In UK Biobank, cannabis use is associated with increased likelihood of depression (OR=1.64, 95% CI=1.59-1.70, p=1.19×10−213) and self-harm (OR=2.85, 95% CI=2.69-3.01, p=3.46×10−304). The strength of this phenotypic association is stronger when more severe trait definitions of cannabis use and depression are considered. Additionally, significant genetic correlations are seen between cannabis use and depression using consortia summary statistics (rg=0.289, SE=0.036, p=1.45×10−15). Polygenic risk scores for cannabis use and depression both explain a small but significant proportion of variance in cannabis use, depression and self harm within a UK Biobank target sample. However, two-sample Mendelian randomisation analyses were not significant.Conclusions: Cannabis use is both phenotypically and genetically associated with depression and self harm. Future work dissecting the causal mechanism linking these traits may have implications for cannabis users.
- 14 February 2019
- Published by Cold Spring Harbor Laboratory in bioRxiv
- p. 549899
Open AccessCannabis use, depression and self-harm: phenotypic and genetic relationships
Background and Aims: The use of cannabis has previously been linked to both depression and self-harm, however the role of genetics in this relationship are unclear. We aimed to examine the phenotypic and genetic relationships between these traits.Design: Genetic and cross-sectional phenotypic data collected through UK Biobank, together with consortia genome-wide association study summary statistics. These data were used to assess the phenotypic and genetic relationship between cannabis use, depression and self harm.Setting: UK, with additional international consortia dataParticipants: N=126,291 British adults aged between 40 and 70 years, recruited into UK BiobankMeasurements: Genome-wide genetic data, phenotypic data on lifetime history of cannabis use, depression and self-harm.Findings: In UK Biobank, cannabis use is associated with increased likelihood of depression (OR=1.64, 95% CI=1.59-1.70, p=1.19×10−213) and self-harm (OR=2.85, 95% CI=2.69-3.01, p=3.46×10−304). The strength of this phenotypic association is stronger when more severe trait definitions of cannabis use and depression are considered. Additionally, significant genetic correlations are seen between cannabis use and depression using consortia summary statistics (rg=0.289, SE=0.036, p=1.45×10−15). Polygenic risk scores for cannabis use and depression both explain a small but significant proportion of variance in cannabis use, depression and self harm within a UK Biobank target sample. However, two-sample Mendelian randomisation analyses were not significant.Conclusions: Cannabis use is both phenotypically and genetically associated with depression and self harm. Future work dissecting the causal mechanism linking these traits may have implications for cannabis users.
- Open Access
- 21 September 2018
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (9) , e0203896
Polygenic risk scores for major depressive disorder and neuroticism as predictors of antidepressant response: Meta-analysis of three treatment cohorts
There are currently no reliable approaches for correctly identifying which patients with major depressive disorder (MDD) will respond well to antidepressant therapy. However, recent genetic advances suggest that Polygenic Risk Scores (PRS) could allow MDD patients to be stratified for antidepressant response. We used PRS for MDD and PRS for neuroticism as putative predictors of antidepressant response within three treatment cohorts: The Genome-based Therapeutic Drugs for Depression (GENDEP) cohort, and 2 sub-cohorts from the Pharmacogenomics Research Network Antidepressant Medication Pharmacogenomics Study PRGN-AMPS (total patient number = 760). Results across cohorts were combined via meta-analysis within a random effects model. Overall, PRS for MDD and neuroticism did not significantly predict antidepressant response but there was a consistent direction of effect, whereby greater genetic loading for both MDD (best MDD result, p < 5*10–5 MDD-PRS at 4 weeks, β = -0.019, S.E = 0.008, p = 0.01) and neuroticism (best neuroticism result, p < 0.1 neuroticism-PRS at 8 weeks, β = -0.017, S.E = 0.008, p = 0.03) were associated with less favourable response. We conclude that the PRS approach may offer some promise for treatment stratification in MDD and should now be assessed within larger clinical cohorts.
- 21 September 2018
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (9) , e0203896
Open AccessPolygenic risk scores for major depressive disorder and neuroticism as predictors of antidepressant response: Meta-analysis of three treatment cohorts
There are currently no reliable approaches for correctly identifying which patients with major depressive disorder (MDD) will respond well to antidepressant therapy. However, recent genetic advances suggest that Polygenic Risk Scores (PRS) could allow MDD patients to be stratified for antidepressant response. We used PRS for MDD and PRS for neuroticism as putative predictors of antidepressant response within three treatment cohorts: The Genome-based Therapeutic Drugs for Depression (GENDEP) cohort, and 2 sub-cohorts from the Pharmacogenomics Research Network Antidepressant Medication Pharmacogenomics Study PRGN-AMPS (total patient number = 760). Results across cohorts were combined via meta-analysis within a random effects model. Overall, PRS for MDD and neuroticism did not significantly predict antidepressant response but there was a consistent direction of effect, whereby greater genetic loading for both MDD (best MDD result, p < 5*10–5 MDD-PRS at 4 weeks, β = -0.019, S.E = 0.008, p = 0.01) and neuroticism (best neuroticism result, p < 0.1 neuroticism-PRS at 8 weeks, β = -0.017, S.E = 0.008, p = 0.03) were associated with less favourable response. We conclude that the PRS approach may offer some promise for treatment stratification in MDD and should now be assessed within larger clinical cohorts.
- Open Access
- 6 July 2017
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 26 (R2) , R160-R165
Advancing psychiatric genetics through dissecting heterogeneity
There has been substantial progress in psychiatric genetics in recent years, through collaborative efforts to build large samples sizes for case/control analyses for a number of psychiatric disorders. The identification of replicated trait-associated genomic loci represents a large stride forward in a field where little is known about the biological processes involved in disorder. As researchers build on this early foundation, they are beginning to advance the field towards more fine-grained approaches that interrogate the many sources of heterogeneity within psychiatric genetics that can obscure the identification of genotypic influences on disorder. In this review, we provide a brief overview, across a range of psychiatric diagnoses, of recent approaches that have been employed to dissect heterogeneity to give a flavour of the current direction of the field. We group these into three main categories; tackling the heterogeneity in phenotype that is found within the diagnostic categories used within psychiatry, the many different forms of genetic variation that might influence psychiatric traits and then finally, the heterogeneity that is seen across individuals of different ancestries.
- 6 July 2017
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 26 (R2) , R160-R165
Open AccessAdvancing psychiatric genetics through dissecting heterogeneity
There has been substantial progress in psychiatric genetics in recent years, through collaborative efforts to build large samples sizes for case/control analyses for a number of psychiatric disorders. The identification of replicated trait-associated genomic loci represents a large stride forward in a field where little is known about the biological processes involved in disorder. As researchers build on this early foundation, they are beginning to advance the field towards more fine-grained approaches that interrogate the many sources of heterogeneity within psychiatric genetics that can obscure the identification of genotypic influences on disorder. In this review, we provide a brief overview, across a range of psychiatric diagnoses, of recent approaches that have been employed to dissect heterogeneity to give a flavour of the current direction of the field. We group these into three main categories; tackling the heterogeneity in phenotype that is found within the diagnostic categories used within psychiatry, the many different forms of genetic variation that might influence psychiatric traits and then finally, the heterogeneity that is seen across individuals of different ancestries.
- Open Access
- 8 May 2017
- Published by Wiley in Human Brain Mapping
- Vol. 38 (8) , 3757-3770
Inferring pathobiology from structural MRI in schizophrenia and bipolar disorder: Modeling head motion and neuroanatomical specificity
Despite over 400 peer‐reviewed structural MRI publications documenting neuroanatomic abnormalities in bipolar disorder and schizophrenia, the confounding effects of head motion and the regional specificity of these defects are unclear. Using a large cohort of individuals scanned on the same research dedicated MRI with broadly similar protocols, we observe reduced cortical thickness indices in both illnesses, though less pronounced in bipolar disorder. While schizophrenia (n = 226) was associated with wide‐spread surface area reductions, bipolar disorder (n = 227) and healthy comparison subjects (n = 370) did not differ. We replicate earlier reports that head motion (estimated from time‐series data) influences surface area and cortical thickness measurements and demonstrate that motion influences a portion, but not all, of the observed between‐group structural differences. Although the effect sizes for these differences were small to medium, when global indices were covaried during vertex‐level analyses, between‐group effects became nonsignificant. This analysis raises doubts about the regional specificity of structural brain changes, possible in contrast to functional changes, in affective and psychotic illnesses as measured with current imaging technology. Given that both schizophrenia and bipolar disorder showed cortical thickness reductions, but only schizophrenia showed surface area changes, and assuming these measures are influenced by at least partially unique sets of biological factors, then our results could indicate some degree of specificity between bipolar disorder and schizophrenia. Hum Brain Mapp 38:3757–3770, 2017. © 2017 Wiley Periodicals, Inc.
- 8 May 2017
- Published by Wiley in Human Brain Mapping
- Vol. 38 (8) , 3757-3770
Open AccessInferring pathobiology from structural MRI in schizophrenia and bipolar disorder: Modeling head motion and neuroanatomical specificity
Despite over 400 peer‐reviewed structural MRI publications documenting neuroanatomic abnormalities in bipolar disorder and schizophrenia, the confounding effects of head motion and the regional specificity of these defects are unclear. Using a large cohort of individuals scanned on the same research dedicated MRI with broadly similar protocols, we observe reduced cortical thickness indices in both illnesses, though less pronounced in bipolar disorder. While schizophrenia (n = 226) was associated with wide‐spread surface area reductions, bipolar disorder (n = 227) and healthy comparison subjects (n = 370) did not differ. We replicate earlier reports that head motion (estimated from time‐series data) influences surface area and cortical thickness measurements and demonstrate that motion influences a portion, but not all, of the observed between‐group structural differences. Although the effect sizes for these differences were small to medium, when global indices were covaried during vertex‐level analyses, between‐group effects became nonsignificant. This analysis raises doubts about the regional specificity of structural brain changes, possible in contrast to functional changes, in affective and psychotic illnesses as measured with current imaging technology. Given that both schizophrenia and bipolar disorder showed cortical thickness reductions, but only schizophrenia showed surface area changes, and assuming these measures are influenced by at least partially unique sets of biological factors, then our results could indicate some degree of specificity between bipolar disorder and schizophrenia. Hum Brain Mapp 38:3757–3770, 2017. © 2017 Wiley Periodicals, Inc.
- Open Access
- 10 April 2017
- Published by Wiley in American Journal of Medical Genetics Part B: Neuropsychiatric Genetics
- Vol. 174 (4) , 427-434
The genome‐wide expression effects of escitalopram and its relationship to neurogenesis, hippocampal volume, and antidepressant response
Antidepressant‐induced hippocampal neurogenesis (AHN) is hypothesized to contribute to increases in hippocampal volume among major depressive disorder patients after long‐term treatment. Furthermore, rodent studies suggest AHN may be the cellular mechanism mediating the therapeutic benefits of antidepressants. Here, we perform the first investigation of genome‐wide expression changes associated with AHN in human cells. We identify gene expression networks significantly activated during AHN, and we perform gene set analyses to probe the molecular relationship between AHN, hippocampal volume, and antidepressant response. The latter were achieved using genome‐wide association summary data collected from 30,717 individuals as part of the ENIGMA Consortium (genetic predictors of hippocampal volume dataset), and data collected from 1,222 major depressed patients as part of the NEWMEDS Project (genetic predictors of response to antidepressants dataset). Our results showed that the selective serotonin reuptake inhibitor, escitalopram evoked AHN in human cells; dose‐dependently increasing the differentiation of cells into neuroblasts, as well as increasing gliogenesis. Activated genome‐wide expression networks relate to axon and microtubule formation, and ribosomal biogenesis. Gene set analysis revealed that gene expression changes associated with AHN were nominally enriched for genes predictive of hippocampal volume, but not for genes predictive of therapeutic response.
- 10 April 2017
- Published by Wiley in American Journal of Medical Genetics Part B: Neuropsychiatric Genetics
- Vol. 174 (4) , 427-434
Open AccessThe genome‐wide expression effects of escitalopram and its relationship to neurogenesis, hippocampal volume, and antidepressant response
Antidepressant‐induced hippocampal neurogenesis (AHN) is hypothesized to contribute to increases in hippocampal volume among major depressive disorder patients after long‐term treatment. Furthermore, rodent studies suggest AHN may be the cellular mechanism mediating the therapeutic benefits of antidepressants. Here, we perform the first investigation of genome‐wide expression changes associated with AHN in human cells. We identify gene expression networks significantly activated during AHN, and we perform gene set analyses to probe the molecular relationship between AHN, hippocampal volume, and antidepressant response. The latter were achieved using genome‐wide association summary data collected from 30,717 individuals as part of the ENIGMA Consortium (genetic predictors of hippocampal volume dataset), and data collected from 1,222 major depressed patients as part of the NEWMEDS Project (genetic predictors of response to antidepressants dataset). Our results showed that the selective serotonin reuptake inhibitor, escitalopram evoked AHN in human cells; dose‐dependently increasing the differentiation of cells into neuroblasts, as well as increasing gliogenesis. Activated genome‐wide expression networks relate to axon and microtubule formation, and ribosomal biogenesis. Gene set analysis revealed that gene expression changes associated with AHN were nominally enriched for genes predictive of hippocampal volume, but not for genes predictive of therapeutic response.
- Open Access
- 6 April 2017
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 37 (18) , 4735-4743
Epigenetic Age Acceleration Assessed with Human White-Matter Images
The accurate estimation of age using methylation data has proved a useful and heritable biomarker, with acceleration in epigenetic age predicting a number of age-related phenotypes. Measures of white matter integrity in the brain are also heritable and highly sensitive to both normal and pathological aging processes across adulthood. We consider the phenotypic and genetic interrelationships between epigenetic age acceleration and white matter integrity in humans. Our goal was to investigate processes that underlie interindividual variability in age-related changes in the brain. Using blood taken from a Mexican-American extended pedigree sample (n= 628; age = 23.28–93.11 years), epigenetic age was estimated using the method developed by Horvath (2013). Forn= 376 individuals, diffusion tensor imaging scans were also available. The interrelationship between epigenetic age acceleration and global white matter integrity was investigated with variance decomposition methods. To test for neuroanatomical specificity, 16 specific tracts were additionally considered. We observed negative phenotypic correlations between epigenetic age acceleration and global white matter tract integrity (ρpheno= −0.119,p= 0.028), with evidence of shared genetic (ρgene= −0.463,p= 0.013) but not environmental influences. Negative phenotypic and genetic correlations with age acceleration were also seen for a number of specific white matter tracts, along with additional negative phenotypic correlations between granulocyte abundance and white matter integrity. These findings (i.e., increased acceleration in epigenetic age in peripheral blood correlates with reduced white matter integrity in the brain and shares common genetic influences) provide a window into the neurobiology of aging processes within the brain and a potential biomarker of normal and pathological brain aging.SIGNIFICANCE STATEMENTEpigenetic measures can be used to predict age with a high degree of accuracy and so capture acceleration in biological age, relative to chronological age. The white matter tracts within the brain are also highly sensitive to aging processes. We show that increased biological aging (measured using epigenetic data from blood samples) is correlated with reduced integrity of white matter tracts within the human brain (measured using diffusion tensor imaging) with data from a large sample of Mexican-American families. Given the family design of the sample, we are also able to demonstrate that epigenetic aging and white matter tract integrity also share common genetic influences. Therefore, epigenetic age may be a potential, and accessible, biomarker of brain aging.
- 6 April 2017
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 37 (18) , 4735-4743
Open AccessEpigenetic Age Acceleration Assessed with Human White-Matter Images
The accurate estimation of age using methylation data has proved a useful and heritable biomarker, with acceleration in epigenetic age predicting a number of age-related phenotypes. Measures of white matter integrity in the brain are also heritable and highly sensitive to both normal and pathological aging processes across adulthood. We consider the phenotypic and genetic interrelationships between epigenetic age acceleration and white matter integrity in humans. Our goal was to investigate processes that underlie interindividual variability in age-related changes in the brain. Using blood taken from a Mexican-American extended pedigree sample (n= 628; age = 23.28–93.11 years), epigenetic age was estimated using the method developed by Horvath (2013). Forn= 376 individuals, diffusion tensor imaging scans were also available. The interrelationship between epigenetic age acceleration and global white matter integrity was investigated with variance decomposition methods. To test for neuroanatomical specificity, 16 specific tracts were additionally considered. We observed negative phenotypic correlations between epigenetic age acceleration and global white matter tract integrity (ρpheno= −0.119,p= 0.028), with evidence of shared genetic (ρgene= −0.463,p= 0.013) but not environmental influences. Negative phenotypic and genetic correlations with age acceleration were also seen for a number of specific white matter tracts, along with additional negative phenotypic correlations between granulocyte abundance and white matter integrity. These findings (i.e., increased acceleration in epigenetic age in peripheral blood correlates with reduced white matter integrity in the brain and shares common genetic influences) provide a window into the neurobiology of aging processes within the brain and a potential biomarker of normal and pathological brain aging.SIGNIFICANCE STATEMENTEpigenetic measures can be used to predict age with a high degree of accuracy and so capture acceleration in biological age, relative to chronological age. The white matter tracts within the brain are also highly sensitive to aging processes. We show that increased biological aging (measured using epigenetic data from blood samples) is correlated with reduced integrity of white matter tracts within the human brain (measured using diffusion tensor imaging) with data from a large sample of Mexican-American families. Given the family design of the sample, we are also able to demonstrate that epigenetic aging and white matter tract integrity also share common genetic influences. Therefore, epigenetic age may be a potential, and accessible, biomarker of brain aging.